P1/2 data • PK/PD data • Clinical Trial,Phase II • Journal • Metastases
|
ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 positive • ROS1 rearrangement
|
Xalkori (crizotinib) • Anboni (unecritinib)